Suppr超能文献

MiR-193a-3p的下调决定了肝癌的恶化:一项临床实时定量逆转录聚合酶链反应研究

Down-Regulation of MiR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study.

作者信息

Liu Yongru, Ren Fanghui, Luo Yihuan, Rong Minhua, Chen Gang, Dang Yiwu

机构信息

Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).

Department of Research, Affiliated Cancer Hospital, Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).

出版信息

Med Sci Monit. 2015 Aug 11;21:2352-60. doi: 10.12659/MSM.894077.

Abstract

BACKGROUND

Although some recent reports have shown that the expression level of miR-193a varied in different cancers, its role in hepatocellular carcinoma (HCC) remains unidentified. The aim of the current study was to validate the relationship between miR-193a-3p and clinicopathological characteristics in HCC patients.

MATERIAL AND METHODS

Expression of miR-193a-3p in 95 HCC cases and their corresponding peritumoral tissues (PT) was examined by using quantitative reverse transcription polymerase chain reaction (qRT-PCR). miR-193a-3p expression and its correlation with a variety of clinicopathological features and patient recurrence were analyzed.

RESULTS

The relative level of miR-193a-3p was 3.2028±1.1951 in PT, significantly higher than its expression in HCC tissues (1.5941±0.7079, P<0.001). The area under the curve of underexpression of miR-193a-3p was 0.906 to distinguish HCC from normal liver (95% CI: 0.864-0.948, P<0.001). Expression of miR-193a-3p was negatively correlated to metastasis (r=-0.371, P=0.000), TNM (r=-0.321, P=0.002), respectively. Additionally, the recurrence time was 50.271±2.631 months for the low miR-193a-3p level group and 60.132±3.626 months for the high miR-193a-3p level group. However, no significant difference between them was found (chi-square=0.354, P=0.552).

CONCLUSIONS

MiR-193a-3p may be a tumor-suppressive miRNA which is down-regulated in HCC tissues. It could be regarded as a predictor for the deterioration of HCC patients.

摘要

背景

尽管最近一些报道显示miR - 193a的表达水平在不同癌症中有所不同,但其在肝细胞癌(HCC)中的作用仍不明确。本研究的目的是验证miR - 193a - 3p与HCC患者临床病理特征之间的关系。

材料与方法

采用定量逆转录聚合酶链反应(qRT - PCR)检测95例HCC病例及其相应癌旁组织(PT)中miR - 193a - 3p的表达。分析miR - 193a - 3p表达及其与各种临床病理特征和患者复发的相关性。

结果

PT中miR - 193a - 3p的相对水平为3.2028±1.1951,显著高于其在HCC组织中的表达(1.5941±0.7079,P<0.001)。miR - 193a - 3p低表达的曲线下面积为0.906,可区分HCC与正常肝脏(95%CI:0.864 - 0.948,P<0.001)。miR - 193a - 3p的表达分别与转移(r = -0.371,P = 0.000)、TNM(r = -0.321,P = 0.002)呈负相关。此外,低miR - 193a - 3p水平组的复发时间为50.271±2.631个月,高miR - 193a - 3p水平组为60.132±3.626个月。然而,两组之间未发现显著差异(卡方=0.354,P = 0.552)。

结论

MiR - 193a - 3p可能是一种在HCC组织中下调的肿瘤抑制性miRNA。它可被视为HCC患者病情恶化的预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b12d/4538786/a8ff89ae023e/medscimonit-21-2352-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验